Ghrp-6 causes prolactin gyno. Throw away your peptides. Buy some test boosters, Divanex and a sh!tload of frozen grilled chicken breasts. Lift hard, eat hard, screw hard. You'll get the most out of your physique long term if you'll leave drugs alone for now. Age will creep on you before you know it.
im pritty sure its Ghrp-2 that can cause this. NOT Ghrp-6.
here is info:
Growth Hormone Releasing Peptide - 2 (GHRP2)
Is a synthetic six amino acid peptide that has robustly potent properties.
GHRPs are a small family of peptides acting at the pituitary and the hypothalamus to release Growth hormone (GH) through the activation of a specific, G protein-coupled receptor.
________________________________________
They were discovered 20 years ago as synthetic metenkephalin- derived oligopeptides (Synthetic tissue derived amino acids). Although it has no structural homology with Growth Hormone Releasing Hormone (GHRH), in clinical studies GHRP-2 demonstrated action on the pituitary to release Human Growth Hormone (HGH). Similar results were effective when GHRP-2 was administered sublingual. Clinical studies showed the most potent GHRP being the hexapeptide GHRP-2.
________________________________________
Growth Hormone Releasing Peptide 2(GHRP2) substantially stimulates the pituitary gland's increased natural production of the body's own endogenous human growth hormone (HGH). This therapy consists of daily periodic sub-lingual dosing. Growth Hormone releasing peptide 2, GHRP2 has shown on it's own to robustly increase IGF-1 levels, and even greater results occurred when used with Growth Hormone Releasing Hormone (GHRH) to which also stimulates the pituitary gland to produce increased natural secretion of human growth hormone. This also boosts the hypothalamus function as well.
________________________________________
The results of the clinical studies published in the Journal of Endocrinology and Metabolism in 1997 for GHRP2 - showed that a medically supervised, prescribed and administered therapy increased growth hormone levels in adults and children, who have growth hormone deficiency.
________________________________________
The increase in the body's growth hormone via elevated IGF-1 levels produced by the pituitary gland in response to GHRP2 therapy -- has an anabolic effect on the tissues of the body and other benefits identified below.
Synergy of GHRH + GHRP
It is well documented and established that the concurrent administration of Growth Hormone Releasing Hormone (GHRH) and a Growth Hormone Releasing Peptide (GHRP-6, GHRP-2 or Hexarelin) results in synergistic release of GH from pituitary stores. In other words if GHRH contributes a GH amount quantified as the number 2 and GHRPs contributed a GH amount quantified as the number 4 the total GH release is not additive (i.e. 2 + 4 = 6). Rather the whole is greater than the sum of the parts such that 2 + 4 = 10.
While the GHRPs (GHRP-6, GHRP-2 and Hexarelin) come in only one half-life form and are capable of generating a GH pulse that lasts a couple of hours re-administration of a GHRP is required to effect additional pulses.
Growth Hormone Releasing Hormone (GHRH) however is currently available in several forms which vary only by their half-lives. Naturally occurring GHRH is either a 40 or 44 amino acid peptide with the bioactive portion residing in the first 29 amino acids. This shortened peptide identical in behavior and half-life to that of GHRH is called Growth Hormone Releasing Factor and is abbreviated as GRF(1-29).
GRF(1-29) is produced and sold as a drug called Sermorelin. It has a short-half life measured in minutes. If you prefer analogies think of this as a Testosterone Suspension (i.e. unestered).
To increase the stability and half-life of GRF(1-29) four amino acid changes where made to its structure. These changes increase the half-life beyond 30 minutes which is more than sufficient to exert a sustained effect which will maximize a GH pulse. This form is often called tetrasubstituted GRF(1-29) (or modified) and unfortunately & confusingly mislabeled as CJC-1295. If you prefer analogies think of this as a Testosterone Propionate (i.e. short-estered).
Note that some may also refer to this as CJC-1295 without the DAC (Drug Affinity Complex).
Frequent dosing of either the aforementioned modified GRF(1-29) or regular GRF(1-29) is required and as previously indicated works synergistically with a GHRP.
In an attempt to create a more convenient long-lasting GHRH, a compound known as CJC-1295 was created. This compound is identical to the aforementioned modified GRF(1-29) with the addition of the amino acid Lysine which links to a non-peptide molecule known as a "Drug Affinity Complex (DAC)". This complex allows GRF(1-29) to bind to albumin post-injection in plasma and extends its half-life to that of days. If you prefer analogies think of this as a Testosterone Cypionate (i.e. long-estered). However this is not accurate. CJC-1295 results in continual GH bleed. Although natural pulsation still occurs CJC-1295 does nothing to increase those pulses. Instead it raises base levels of GH and creates a more feminized pattern of release. This not desirable.
Modified GRF(1-29)however when combined with a GHRP brings about a substantial pulse which has desirable effects.
A Brief Summary of Dosing and Administration
Dosing GHRPs
The saturation dose in most studies on the GHRPs (GHRP-6, GHRP-2, Ipamorelin & Hexarelin) is defined as either 100mcg or 1mcg/kg.
What that means is that 100mcg will saturate the receptors fully, but if you add another 100mcg to that dose only 50% of that portion will be effective. If you add an additional 100mcg to that dose only about 25% will be effective. Perhaps a final 100mcg might add a little something to GH release but that is it.
So 100mcg is the saturation dose and you could add more up to 300 to 400mcg and get a little more effect.
A 500mcg dose will not be more effective then a 400mcg, perhaps not even more effective then 300mcg.
The additional problems are desensitization & cortisol/prolactin side-effects.
--------------------------------------------------
INFO: GHRP-6 (Growth Hormone Releasing Peptide – 6)
________________________________________
GHRP-6: GHRP-6 (Growth Hormone Releasing Peptide – 6) is a hexapeptide with a chain comprised of 6 amino acids. This special sequence is considered to provide a signal to the body to begin secreting Growth Hormone(GH) release while also blocking Somatostatin, a hormone that inhibits Growth Hormone release. Growth Hormone has host of beneficial effects such as decreased body fat, increased muscle, and increased strength and stamina so maximizing the production and secretion can be a great addition to improved animal physical shape. Increased amounts of Growth Hormone then can cause the Liver to secrete the hormone IGF-1 which has also been implicated in improving the animal body’s ability to burn fat and build muscle. Clinical cases have shown that the use of GHRP-6 was associated with increased muscle mass and a reduction of body fat.
Dosage - 250-500mcg daily
Growth hormone releasing hexapeptide
From Wikipedia, the free encyclopedia
Growth hormone releasing hexapeptide
IUPAC name[hide]
L-histidyl-D-tryptophyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-Lysinamide
Other names[hide]
GHRP-6
Identifiers
CAS number
87616-84-0
PubChem
5486806
MeSH
Growth+hormone+releasing+hexapeptide
Jmol-3D images Image 1
SMILES
[show]
Properties
Molecular formula
C46H56N12O6
Molar mass
873.014
Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)
Infobox references
Growth hormone releasing hexapeptide (GHRP6) is one of several synthetic met-enkephalin analogs that include unnatural D-amino acids, were developed for their growth hormone (GH) releasing activity and are called GH secretagogues. They lack opioid activity but are potent stimulators of GH release. These secretagogues are distinct from growth hormone releasing hormone (GHRH) in that they share no sequence relation and derive their function through action at a completely different receptor. This receptor was originally called the GH secretagogue receptor, the hormone ghrelin is now considered the receptor's natural endogenous ligand. Therefore, these GH secretagouges act as synthetic ghrelinmimetics.
The major side effect accompanied by the use of GHRP-6 or other GH secretagogues is a significant increase in appetite because secretagogues mimic the action of Ghrelin, a peptide which is released naturally in the lining of the stomach and increases hunger and gastric emptying.
GHRP-6, other secretagogues and ghrelin stimulate the anterior pituitary gland causing an increase in GH release. When natural GH secretion has been inhibited by long term abuse of synthetic GH, GHRP-6 may help to re-stimulate the natural production of GH. GHRP-6 may also affect the central nervous system by protecting neurons as well as increasing strength in a way very similar to the way certain steroids in the Dihydrotestosterone family do.
Claimed benefits of increased Growth Hormone levels through GHRP-6 stimulation include: an increase in strength, muscle mass and body fat loss, rejuvenation and strengthening of joints, connective tissue and bone mass. Enhanced GH secretion also leads to the liver secreting more IGF-1 (Insulin-Like Growth Factor 1), which is thought to be the primary anabolic mechanism of action for Growth Hormone.
[edit] Technical data
It has also been discovered that when GHRP-6 and insulin are used simultaneously, GH response to GHRP-6 is increased (1). A recent study in normal mice showed significant differences in body composition, muscle growth, glucose metabolism, memory and cardiac function in the mice being administered the GHRP-6 (2). There are still many questions regarding this fairly new compound, scientists are hoping to gain a better clinical understanding of the peptide through further research over the next few years.
[edit] References
• Korbonits M, Goldstone AP, Gueorguiev M, Grossman AB (2004). "Ghrelin--a hormone with multiple functions". Frontiers in neuroendocrinology 25 (1): 27–68. doi:10.1016/j.yfrne.2004.03.002. PMID 15183037.
• {{Penlava, A, et. al. Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man.}}
• Template:J Clin Endocrinol Metab. 1993 Jan;76(1):168-71. Adeghate, E. & Ponery, A.S. (2002) Ghrelin stimulates insulin secretion from the pancreas of normal and diabetic rats. Journal of Neuroendocrinology, 14, 555560.
